124 related articles for article (PubMed ID: 34565137)
1. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Stępień PM; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Zarębska-Michaluk D
Pol Arch Intern Med; 2021 Nov; 131(11):. PubMed ID: 34565137
[TBL] [Abstract][Full Text] [Related]
2. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
[TBL] [Abstract][Full Text] [Related]
3. Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
Tronina O; Brzdęk M; Zarębska-Michaluk D; Dybowska D; Lorenc B; Janczewska E; Mazur W; Parfieniuk-Kowerda A; Piekarska A; Krygier R; Klapaczyński J; Berak H; Jaroszewicz J; Garlicki A; Tomasiewicz K; Citko J; Flisiak R
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992388
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.
Jaroszewicz J; Zarębska-Michaluk D; Janocha-Litwin J; Parfieniuk-Kowerda A; Sitko M; Piekarska A; Białkowska J; Dybowska D; Murawska-Ochab A; Flisiak R
Pol Arch Intern Med; 2023 Mar; 133(3):. PubMed ID: 36602060
[TBL] [Abstract][Full Text] [Related]
5. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
6. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
Zarębska-Michaluk D; Buczyńska I; Simon K; Tudrujek-Zdunek M; Janczewska E; Dybowska D; Sitko M; Dobracka B; Jaroszewicz J; Pabjan P; Klapaczyński J; Laurans Ł; Mazur W; Socha Ł; Tronina O; Parczewski M; Flisiak R
Can J Gastroenterol Hepatol; 2019; 2019():4029541. PubMed ID: 30941326
[TBL] [Abstract][Full Text] [Related]
7. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
8. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Dobrowolska K; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Stępień P; Zarębska-Michaluk D
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062302
[TBL] [Abstract][Full Text] [Related]
9. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
10. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
12. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.
Scotto R; Buonomo AR; Moriello NS; Maraolo AE; Zappulo E; Pinchera B; Gentile I; Borgia G
Rev Recent Clin Trials; 2019; 14(3):173-182. PubMed ID: 30848211
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and antiviral therapy in patients infected with hepatitis C virus in the interferon‑free era.
Brzdęk M; Dobrowolska K; Pabjan P; Zarębska-Michaluk D
Pol Arch Intern Med; 2022 Sep; 132(9):. PubMed ID: 35938950
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
19. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
20. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
Brzdęk M; Zarębska-Michaluk D; Invernizzi F; Cilla M; Dobrowolska K; Flisiak R
World J Gastroenterol; 2023 Feb; 29(6):949-966. PubMed ID: 36844142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
